Compare Citius Pharmaceuticals Inc (CTXR) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs S&P500 ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while S&P500 ETF trades at $778.54 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 60318.6× Citius Pharmaceuticals Inc's market cap, and S&P500 ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and S&P500 ETF for 205 Days on average.
| CTXR | SPY | |
|---|---|---|
Market Cap | $13.62M | $821.54B |
Volume | 132,438 | 40,070,358 |
Sector | Health | — |
52-Week High | $1.82 | $779.14 |
52-Week Low | $0.48 | $631.99 |
Typical Hold Time | 17 Days | 205 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
SPY, tracking the S&P 500, trades at $773.97, down 0.42% over 24 hours, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF is near its pivot point of $774, with support at $771 and resistance at $777. Recent news highlights mixed sentiment, with some articles pointing to strong profit growth in 2026 but expectations of a slowdown in 2027, while others discuss defensive positioning and valuation concerns amid market volatility.
The outlook for SPY remains tied to broader market dynamics, with potential upside from continued corporate earnings growth but risks from economic slowdowns and elevated valuations. Investors face opportunities from historical year-end rallies cited by analysts, yet must weigh risks like margin debt warnings and profit growth deceleration. Key factors include upcoming economic data and institutional flows influencing near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
